Table 3. The chemotherapy response according to the rs351855G/A genotypes.
NSCLC | Control | Adjusted | 95% CI | Adjusted | |||||
---|---|---|---|---|---|---|---|---|---|
n | % | n | % | OR | P valuea | ||||
rs351855G/A | GG | 90 | 30.93 | 103 | 30.47 | 1.00 | |||
GA | 126 | 43.30 | 205 | 60.65 | 0.70 | 0.49 | 1.01 | 0.055 | |
AA | 75 | 25.77 | 30 | 8.88 | 2.86 | 1.72 | 4.76 | <0.001 | |
G | 306 | 52.58 | 411 | 60.80 | 1.00 | ||||
A | 276 | 47.42 | 265 | 39.20 | 1.40 | 1.12 | 1.75 | 0.003 |
aBinary logistic regression was applied; data was adjusted with gender, age, tumor histology, disease stage, and chemotherapy regimen.